In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment

International Journal of Radiation Oncology Biology Physics

Volumn 49, Issue 2, 2001, Pages 443-450

  Landuyt, Willy ^a,b   Ahmed, Bisan ^a   Nuyts, Sandra ^a   Theys, Jan ^a,c   Op de Beeck, Michel ^d   Rijnders, Alex ^e   Anné, Jozef ^c   Oosterom, Allan van ^b   Van den Bogaert, Walter ^e   Lambin, Philippe ^a,e  

^a Laboratory of Experimental Oncology   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d University Animal Housing Unit   (Belgium)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Anti angiogenesis; Combretastatin A 4 phosphate; Radiotherapy; TNP 470; Tumor growth delay; Tumor size; Vascular targeting

Indexed keywords

ANGIOGENESIS INHIBITOR; COMBRETASTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER RADIOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; IONIZING RADIATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RHABDOMYOSARCOMA; TUMOR GROWTH; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COMBINED MODALITY THERAPY; CYCLOHEXANES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; RADIOTHERAPY DOSAGE; RATS; RHABDOMYOSARCOMA; SESQUITERPENES; STILBENES; TRANSPLANTATION, HETEROLOGOUS;

EID: 0035254653     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)01470-X     Document Type: Conference Paper

References (34)

1. The role of angiogenesis in tumor growth
2. What is the evidence that tumors are angiogenesis dependent?
3. Review article; Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy
4. Designing therapies that target tumor blood vessels
5. Antivascular approaches to solid tumor therapy; Evaluation of vinblastine and flavone acetic acid
6. Vinca alkaloids; Anti-vascular effects in a murine tumour
7. Combretastatin A4. An agent that displays potent and selective toxicity towards tumour vasculature
8. Anti-vascular approaches to solid tumor therapy; Evaluation of combretastatin A-4 phosphates
9. 3H mouse mammary carcinoma and a variety of murine spontaneous tumors
10. Combretastatin A-4 phosphate as a tumor vascular-targeting agent; Early effects in tumors and normal tissues
11. 4An rat glioma
12. Vascular targeting of solid tumours; A major 'inverse' volume-response relationship with combretastatin A-4 phosphate in rat rhabdomyosarcoma
13. Tumor volume; A basic and specific response predictor in radiotherapy
14. Tumour size in cancer of the cervix
15. Inhibition of tumor angiogenesis
16. Angiogenesis inhibition; A review
17. Cellular proliferation patterns in an experimental rhabdomyosarcoma in the rat
18. The unique physiology of solid tumors; Opportunities (and problems) for cancer therapy
19. Antiangiogenesis for cancer therapy
20. In vivo targets of recombinant human tumour necrosis factor α; Blood flow, oxygen consumption and growth of isotransplanted rat tumours
21. Arsenic trioxide cancer selective necrosis in solid murine tumors by vascular shutdown
22. Vascular targeting and the inhibition of angiogenesis
23. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4
24. Tubulin/microtubules; Still a promising target for new chemotherapeutic agents
25. Combined effects of angiostatin and ionizing radiation in antitumour therapy
26. Combined effects of TNP-470 and Taxol in human non-small cell lung cancer cell lines
27. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents
28. The effect of a single fraction compared to multiple fractions on painful bone metastases; A global analysis of the Dutch Bone Metastases Study
29. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain; Randomized comparison with a multifraction schedule over 12 months of patient follow-up
30. Colonization of Clostridium in the body is restricted to hypoxic and necrotic areas of tumors
31. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate; Effects on radiation therapy
32. Analysis of experimental antiangiogenic therapy